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Abstract
Background: TRPV6 is over-expressed and promotes the proliferation and invasion in many cancers. The association
between the expression of TRPV6 and clinical outcome in esophageal squamous cell carcinoma (ESCC) has not been
studied yet. We aim to elucidate the role of TRPV6 in predicting prognosis of patients with ESCC.
Methods: In the retrospective study, mRNA level of TRPV6 was examined in patients (N = 174) from Sun Yat-sen
University Cancer Center (mRNA cohort) and protein level of TRPV6 was examined in patients (N = 218) from Linzhou
Cancer Hospital (protein cohort). Statistical analysis was performed to test the clinical and prognostic significance of
TRPV6.
Results: TRPV6 was down-regulated in ESCC tissues and cell lines. Patients with downregulation of TRPV6
trended to have a higher rate of advanced pT stage in both mRNA cohort (P = 0.089) and protein cohort
(P = 0.073), though not statistically significant. No significant association was observed between TRPV6 expression and
disease-specific survival (DSS) in both two cohorts. However, stratified survival analysis based on the gender showed
that in mRNA cohort, downregulation of TRPV6 was associated with an unfavorable 3-year DSS in patients with male
(47.3 % vs 63.6 %, P = 0.027) and with favorable 3-year DSS in patients with female (66.7 % vs 43.0 %, P = 0.031). The
result was confirmed in protein cohort. Male patients with downregulation of TRPV6 had a poor 3-year DSS (20.0 % vs
57.1 %,P < 0.001) while female counterparts showed an enhanced 3-year DSS (56.1 % vs 28.6 %, P = 0.005).
Conclusion: TRPV6 is down-regulated in ESCC. As a predictive biomarker, TRPV6 plays a Janus-like role in predicting
survival of male and female ESCC patients.
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Background
Esophageal cancer is one of the most aggressive malig-
nancies worldwide, with more than 480,000 new cases
and 400,000 deaths annually. In China, esophageal squa-
mous cell carcinoma (ESCC) ranks 4th among most
common causes of death and remains a major burden
for public health [1]. Despite advances of surgical tech-
niques and incorporation of new therapeutic approaches,
ESCC is still a highly devastating disease with poor prog-
nosis, 5-year overall survival at less than 40 % [2, 3].
Current researches have been focusing on prognostic
predictor of ESCC in order to actively adapt therapies
for the high-risk subpopulations.
Transient receptor potential (TRP) channels are a
large family of nonselective ion channel which play a key
role in a variety of physiological function [4]. More im-
portantly, most of these channels have been proved to
be associated with several diseases including cancers [5].
Several channels were identified to play crucial roles in
the progression and prognosis of cancers [6–10].
TRPV6 (transient receptor potential vanilloid 6), is
one of the most highly calcium selective channel among
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all TRP channels. Compared to other TRP channels,
TRPV6 is characterized by its high selectivity for calcium
and its active role in Ca2+-related intracellular pathway
[11, 12]. Several studies have demonstrated that TRPV6
is over-expressed and promotes the proliferation and in-
vasion in many cancers, such as prostate cancer [9, 13],
breast [8, 14, 15] and colon cancer [16]. Lehen’kyi et al.
[13] showed that TRPV6 is positively involved in regula-
tion of proliferation in prostate cancer cell line LNCaP.
Genetic silencing of TRPV6 leads to decreased prolifera-
tion rate, cell accumulation into S-phase of the cell
cycle, and proliferating cell nuclear antigen (PCNA) ex-
pression. The study also revealed that Ca2+ uptake into
LNCaP cells is mediated by TRPV6, with the subsequent
downstream activation of nuclear factor of activated T
cells (NFAT). High expression of TRPV6 mRNA in pros-
tate cancer is closely associated with the elevated degree
of aggressiveness of the cancer, assessed by the Gleeson
score (grading of the pathological stage) and extrapro-
static extension [9]. Besides, TRPV6 is mainly over-
expressed in the invasive breast cancer cells and selective
silencing of TRPV6 inhibits migration and invasion of
breast cancer [15]. Patients with high expression of
TRPV6 exhibits a worse survival when compared to
those with low or intermediate TRPV6 expression in
breast cancer [14]. These observations suggested that
TRPV6 has oncogenic potential and could be used as a
biomarker to predict the clinical outcome in most can-
cers. On the other hand, however, some studies indi-
cated that TRPV6 might play antitumour role in some
cancer types, such as colon cancer [17, 18]. Curcumin,
which is a ligand of 1,25-vitamin D3 receptor that up-
regulated TRPV6 in vivo, may play a role similar to that
of 1,25-vitamin D3 in promoting calcium uptake as part
of the protective effect against colon cancer [17]. Other
study showed that TRPV6 can mediate capsaicin-
induced apoptosis in gastric cells [18]. Studies thus far
have shown that TRPV6 plays very complicated roles
among different cancer types. Nevertheless, the expres-
sion pattern of TRPV6 in ESCC and its value in predict-
ing the survival of patients has not been elucidated yet.
Therefore, we aim to clarify the TRPV6 expression in
primary ESCC and analyze the relation with prognosis
in ESCC patients.
Methods
Patients and tissues specimens
In our retrospective study, 174 consecutive patients of
ESCCs tissues and 45 patients of paired adjacent nontu-
mor tissues were collected immediately after surgery
resection at Sun Yat-sen University Cancer Center from
March 2002 to October 2008 [10, 19]. As a validation, a
total of 300 patients of formalin-fixed, paraffin-embedded
ESCC tumor specimens and the corresponding normal
epithelia were selected from another institute, Linzhou
Cancer Hospital [20]. The cases selected were based on
criteria described previously [10]. Briefly, inclusion criteria
were as follows: histologic proof of thoracic ESCC,
complete surgical resection (R0), and complete follow-up
data. The exclusion criteria were: received neoadjuvant or
adjuvant treatment, history of other malignancy, death in
perioperative period, and cervical lymph nodes metastases.
The preoperative workup was evaluated by endoscopy with
biopsy and histologic examination, barium esophagography
to confirm tumour location, thoracic and abdominal com-
puted tomography (CT), and cervical ultrasonography
(with biopsy if indicated) if cervical lymph node metastasis
was suspected. Histological differentiation, pT category
(depth of tumor invasion), and pN category (lymph node
metastasis) were determined by pathologic examination.
All patients gave written informed consent before oper-
ation. The study was approved by the Ethics Committee of
the Cancer Center of Sun Yat-sen University and Linzhou
Cancer Hospital.
Cell culture
The ESCC cell lines, including KYSE30, KYSE140,
KYSE180, KYSE 410, KYSE510, KYSE520, HKESC1,
CE81T, EC109 and EC9706were all kindly provided by
Prof. Xinyuan Guan from Hong Kong University, and
maintained in Dulbecco’s Modified Eagle Medium sup-
plemented with 10 % fetal bovine serum and 10 %
penicillin-streptomycin at 37 °C in a humidified incuba-
tor containing 5 % CO2.
Quantitative Real-time Polymerase Chain Reaction
(qRT-PCR) assays
The fresh tumorous and non-tumorous samples were
taken from regions which macroscopically judged to be
neoplastic and normal, respectively. Both of them were
immediately stored at dry ice after resection and then fro-
zen at −80 °C. Total RNA of the specimens and exponen-
tially growing cells were extracted by TRIzol reagent
(Invitrogen) according to manufacturer’s instruction. Each
cDNA was synthesized from 1 μg of total RNA using
RevertAid First Strand cDNA Synthesis Kit (Thermo Sci-
entific), and stored at −80 °C. cDNA was subjected to
quantitative Real-Time PCR (qRT-PCR) for TRPV6.
GAPDH was used as internal control. The primers used
were as follows: TRPV6, forward primer 5'-CGTGT
TCTCACTTCGCTTCCTGG-3' and reverse primer 5'-
TGGCGTTCATGCTACTCCTCTTTC-3' [NCBI: NM_01
8646.5]; GAPDH, forward primer 5'-ACTTCAACAGCG
ACACCCACTC-3' and reverse primer 5'-TACCAGGAA
ATGAGCTTGACAAAG-3' [NCBI: NM_001256799.1].
qRT-PCR was done using the Power SYBR Green PCR
Master Mix(Applied Bio systems) and LightCycler480
384-well PCR system (Roche Diagnostics). An initial
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denaturing step at 95 °C for 10 min and 40 cycles at
95 °C for 10 s, 60 °C for 20 s, and 72 °Cfor 30 s. The
assays were done in triplicate and values were nor-
malized using the internal control. Quantitative data
were exported and TRPV6 expression was normalized
by internal control. PCR products were subjected to dissoci-
ation curve analysis to exclude amplification of nonspecific
products. The value of relative expression was calculated
using the 2-△△Ct method. △△Ct(sample) =△Ct(sample)-
△Ct(calibrator), △Ct(sample) =Ct(sample) of TRPV6-
Ct(sample) of GAPDH; △Ct(calibrator) = Ct(calibrator) of
TRPV6-Ct(calibrator) of GAPDH; Calibrator was defined as
the pooled samples from 45 patients of adjacent nontumor
tissues [10, 19].
ESCC tissue microarray and immunohistochemical
staining
The ESCC tissue microarray (TMA) with a total of 300
formalin-fixed, paraffin-embedded ESCC tumor speci-
mens and the corresponding normal epithelia was kindly
provided by Prof. Xinyuan Guan from State Key Labora-
tory of Oncology in Southern China, Sun Yat-Sen Uni-
versity Cancer Center. The ESCC tissue microarray was
constructed as described previously [20, 21]. Briefly,
TMA were constructed with a Beecher Instruments tis-
sue microarrayer (Beecher Instruments, Sun Prairie,
WI). Three targeted core samples with a 1-mm diameter
of each specimen were punched and arrayed on a recipi-
ent paraffin block to construct the tissue microarray. For
immunohistochemical (IHC) analysis, the slides were
deparaffinized, rehydrated, and blocked by 10 % normal
goat serum at room temperature for 30 min. The slides
were then incubated with rabbit polyclonal antibody
against TRPV6 (alomone labs) at a dilution of 1:50 at 4 °C
overnight and subsequently incubated with biotinylated
goat anti-rabbit immunoglobulin at a concentration of
1:100 for 30 min at 37 °C. A staining index (values 0–7)
was calculated by adding the scores for the intensity of
TRPV6-positive staining (negative, 0; weak, 1; moderate,
2; or strong, 3) and the percentage of TRPV6-positive cells
(<25 %, 1; 25 %–50 %, 2, >50 %–75 %, 3; ≥ 75 %, 4 scores).
Two independent observers blinded to the clinicopath-
ologic information performed the evaluation of TRPV6
expression. If the two observers conflicted with each
other, a third independent observer was asked to deter-
mine the final result.
Statistical methods
Receiver operative characteristic (ROC) curve generated
by MedCalc 9.6.2.0 (MedCalc Software, Mariakerke,
Belgium) was used to determine the cutoff value for
TRPV6 mRNA expression that yielded the highest
combined sensitivity and specificity with respect to dis-
tinguishing disease specific 5-year survivors from non-
survivors [10, 22]. Statistical analysis was performed
using the SPSS 16.0 for windows software system
(SPSS Inc, Chicago, IL). Paired t test was adopted to
compare the expression of TRPV6 mRNA in 45 pairs
of primary ESCCs between tumor tissues and nontu-
mor tissues. The correlation between TRPV6 expres-
sion and clinicopathologic parameters in mRNA
cohort and protein cohort was analyzed by Chi-
square test where applicable. Disease specific survival
(DSS) was calculated from the time of surgery to the
time of death from ESCC or last follow-up. To the
time of last follow-up or death from disease other
than ESCC, at which point, the data was censored.
The prognostic value using expression of TRPV6 for
predicting survival were calculated by the Kaplan-
Meier method and analyzed by log-rank test. To de-
termine independent factors that were significantly
related to the prognosis, multivariate analysis was per-
formed using Cox’s proportional hazards regression
model with a forward stepwise procedure (the entry and
removal probabilities were 0.05 and 0.10, respectively). A
significant difference was declared if the P value from a
two-tailed test was less than 0.050.
Results
TRPV6 was frequently down-regulated in ESCC
The mRNA expression of TRPV6 was initially tested in
45 pairs of primary ESCC tumors and their adjacent
nontumor tissues by qPCR. Downregulation of TRPV6
was detected in 32 of 45 (71.1 %) of ESCC tumors com-
pared with paired adjacent nontumor tissues (defined as
a 2-fold decrease of TRPV6 expression in tumors)
(Fig. 1a). The relative expression level of TRPV6 was sig-
nificantly down-regulated in tumor tissues compared
with paired adjacent nontumor tissues (P < 0.001,
Fig. 1b). The expression levels of TRPV6 in ten ESCC
cell lines were also tested by qRT-PCR, and the results
showed that TRPV6 was down-regulated in all of them,
compared with pooled samples from 45 nontumor tis-
sues (Np) (Fig. 1c).
TRPV6 expression in protein level was further studied
in 300 primary ESCCs by IHC using a TMA. Informative
IHC results were obtained from 244 pairs of ESCCs.
Noninformative samples included lost samples, unrepre-
sentative samples, and samples with too few tumor cells;
such were not used in data complication. The staining
index of TRPV6 in each informative nontumor tissue
was equal or greater than 5; therefore, staining index 5–
7 was counted as normal expression of TRPV6 whereas
0–4 was counted as downregulation of TRPV6. Using
this designation, downregulation of TRPV6 was detected
in 118 of 244 (48.4 %) informative ESCC tissues com-
pared with their adjacent nontumor tissues (Fig. 2).
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Fig. 1 TRPV6 was down-regulated in esophageal squamous cell carcinoma. TRPV6 mRNA was markedly decreased in tumor tissues than that in
paired adjacent non-tumor tissues (a and b). TRPV6 mRNA was down-regulated in ten esophageal squamous cell carcinoma cell lines when compared
with pooled samples from 45 patients of adjacent non-tumor tissues (Np) (c)
Fig. 2 Representative of TRPV6 expression in three pairs of ESCC tumor and adjacent non-tumor tissue detected by immunostaining with anti-TRPV6
antibody (brown). (magnification: 100×)
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Clinical and pathological data
174 patients with primary ESCCs from Sun Yat-sen Uni-
versity Cancer Center (mRNA cohort) and 218 patients
with primary ESCCs from Linzhou Cancer Hospital
(protein cohort) were recruited in this study. 26 out of
244 patients from Linzhou Cancer Hospital were ex-
cluded according to the exclusion criteria. In mRNA co-
hort, the optimal cutoff value of TRPV6 with the best
discriminatory power was determined to be 0.207 based
on the ROC curve. At this threshold of TRPV6, the sen-
sitivity was 63.1 %, the specificity was 43.3 %. Then,
TRPV6 mRNA expression in mRNA cohort was divided
into two groups: downregulation (≤0.207, n = 66) and
normal expression (>0.207, n = 108) group. Follow-up
data were obtained from all patients, with a median
survival of 39 months in mRNA cohort (range, 2–
105months) and 24 months in protein cohort (range,
1–60months). According to the 7th edition AJCC
staging system [23] and our demographic data, the
clinicopathologic features were dichotomized for stat-
istical analyses as shown in Table 1.
Clinical significance of TRPV6 expression in primary ESCC
patients
The association between TRPV6 expression and clinico-
pathological features in mRNA cohort and protein co-
hort was summarized in Table 1. The result showed that
patients with downregulation of TRPV6 trended to have
a higher rate of advanced pT stage in both mRNA cohort
(P = 0.089) and protein cohort (P = 0.073), but did not
reach the significance. No significant association was
observed between TRPV6 expression and age, gender,
tumor location, histological differentiation, pN cat-
egory and pathological stage either in mRNA cohort
or protein cohort.
Relation between TRPV6 expression and patients survival
Kaplan-Meier analysis showed that patients with down-
regulation of TRPV6 trended to have a poorer 3-year
disease specific survival (DSS) in mRNA cohort (53.8 %
vs 59.6 %, P = 0.531, Fig. 3a) and in protein cohort
(34.0 % vs 42.9 %, P = 0.244, Fig 3b), though not statisti-
cally significant. Univariate analysis showing in Table 2
Table 1 The association between TRPV6 expression and clinicopathologic features in patients with ESCC
Characteristic mRNA cohort Protein cohort
Case Downregulation (%) Pa Case Downregulation (%) Pa
Age 0.827 0.407
≤ 58 72 28(38.9) 113 58(51.3)
> 58 102 38(37.3) 105 48 (45.7)
Gender 0.298 0.093
Male 126 45(35.7) 121 65(53.7)
Female 48 21(43.8) 97 41(42.3)
Location 0.992 0.364
Upper 35 13(37.1) 49 20(40.8)
Middle 94 36(38.3) 152 76(50.0)
Lower 45 17(37.8) 17 10(58.8)
Differentiation 0.133 0.398
Grade 1 41 16(39.0) 24 14(58.3)
Grade 2 91 29(31.9) 147 67(45.6)
Grade 3 42 21(50.0) 47 25(53.2)
pT category 0.089 0.073
T1–2 43 15(34.4) 80 37(46.7)
T3–4 131 64(48.8) 138 82(59.3)
pN category 0.854 0.459
N0 96 37(38.5) 124 63(50.8)
N1–3 78 29(37.2) 94 43(45.7)
Pathological staging 0.827 0.365
I–II 101 39(38.6) 137 67(48.8)
III 73 27(37.0) 81 42(52.2)
aChi-square test
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demonstrated that pT category (P = 0.040 and 0.002, re-
spectively, Figs. 4a, 5b), pN category (P < 0.001 and
0.001, respectively, Figs. 4b, 5c) and pathological staging
(P < 0.001 and 0.001, respectively, Figs. 4c, 5d) were
closely associated with 3-year DSS in both cohorts.
Histological differentiation was found to be significantly
associated with DSS only in protein cohort (P = 0.010,
Fig. 5a) but not in mRNA cohort (P = 0.330). Further
multivariate survival analysis showed that pN category
(HR = 2.95, 95 % CI:1.89-4.62, P < 0.001) was an inde-
pendent prognostic factor in mRNA cohort, pN category
(HR = 2.93, 95 % CI:2.07-4.15, P < 0.001) and histological
differentiation (HR = 1.58, 95 % CI:1.16-2.15, P = 0.004)
were independent prognostic factors in protein cohort
(Table 3).
Due to the expression of TRPV6 regulated by sex ster-
oid hormones, we conducted stratified survival analysis
based on the gender. In mRNA cohort, downregulation
of TRPV6 was significantly associated with an unfavor-
able 3-year DSS in patients with male (47.3 % vs 63.6 %,
P = 0.027, Fig. 6a), while downregulation of TRPV6 was
significantly related with a favorable 3-year DSS in pa-
tients with female (66.7 % vs 43.0 %, P = 0.031, Fig. 6b).
More importantly, the result was validated in protein
cohort. Male patients with downregulation of TRPV6
had a poor 3-year DSS (20.0 % vs 57.1 %,P < 0.001,
Fig. 6c) and female patients with downregulation of
TRPV6 had an increased 3-year DSS (56.1 % vs
28.6 %, P = 0.005, Fig. 6d).
Fig. 3 Kaplan-Meier curves showed that no significant association
between TRPV6 expression and disease-specific survival of esophageal
squamous cell carcinoma was noted either in mRNA cohort (a)
or protein cohort (b)
Table 2 Univariate analysis of TRPV6 expression and
clinicopathological factors for disease specific survival in
patients with ESCC
Characteristic mRNA cohort Protein cohort
3-year DSS (%) Pa 3-year DSS (%) Pa
TRPV6 expression 0.531 0.244
Downregulation 53.8 34.0
Normal expression 59.6 42.9
Age 0.145 0.448
≤ 58 60.6 38.9









Grade 1 62.6 54.2
Grade 2 60.7 40.8
Grade 3 45.4 23.4
pT category 0.040 0.002
T1–2 66.4 52.5
T3–4 55.6 30.4
pN category <0.001 <0.001
N0 74.0 54.0
N1–3 37.5 18.1
Pathological staging <0.001 <0.001
I–II 72.1 53.3
III 37.5 13.6
aKaplan-Meier method (log-rank test)
DSS, disease specific survival
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Fig. 4 Univariate analysis showed that pT category (a), pN category (b), and pathological staging (c) were significantly associate disease specific
survival of patients with esophageal squamous cell carcinoma in the mRNA cohort
Fig. 5 Univariate analysis showed that differentiation (a), pT category (b), pN category (c), and pathological staging (d) were significantly
associate disease specific survival of patients with esophageal squamous cell carcinoma in the protein cohort
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Discussion
In our study, we demonstrated that TRPV6 is generally
down-regulated in ESCC tissues and cell lines. In both
mRNA cohort and protein cohort, downregulation of
TRPV6 is associated with unfavorable survival in male
patients and with favorable survival in female patients.
To the best of our knowledge, this is the first study to
report the expression profile of TRPV6 in ESCC and its
unique Janus-like role in predicting survival of male and
female patients.
TRPV6 has been found to be expressed in normal epi-
thelia from various organs, for instance, the linings of
the gastrointestinal tract, kidney and so on [24, 25].
When compared with normal tissue or cells, the in-
creased expression of TRPV6 at the mRNA and protein
levels has been observed in prostate cancer [9, 13],
breast cancer [8, 14, 15] and colon cancer [16]. Add-
itionally, TRPV6 has been demonstrated to play a crucial
role in promoting the progression of prostate cancer
[13] and breast cancer [8]. One study found that TRPV6
mediates Ca2+ uptake into prostate cancer cell, subse-
quently activating downstream nuclear factor of acti-
vated T cells (NFAT) to promote the proliferation rate,
and proliferating cell nuclear antigen (PCNA) expression
[13]. However, our current study found that TRPV6 is
frequently down-regulated in ESCC. Downregulation of
TRPV6 in mRNA level was detected in 32 of 45 (71.1 %)
of ESCC tumors and in 118 of 244 (48.4 %) informative
ESCC tissues in protein level when compared with
paired adjacent nontumor tissues. Besides, TRPV6 is
down-regulated in ten ESCC cell lines when compared
with pooled samples from 45 nontumor tissues (Np).
Our result is consistent with a previous study by Wu
et al.[26] which the expression of TRPV6 at protein and
mRNA levels is markedly decreased in renal cell carcin-
oma than that in normal kidney tissue. Although the
study only included twenty seven patients with renal cell
carcinoma and did not detect the expression of TRPV6
in renal cell lines, the findings lend support to our claim
that TRPV6 could be down-regulated in some cancer
types. Thus, these findings suggested that expression of
TRPV6 in cancers could be tissue-specific and lend
Table 3 Multivariate survival analysisa for disease specific
survival in patients with ESCC
Prognostic
factor
mRNA cohort Protein cohort
HR 95 % CI P HR 95 % CI P
Differentiation - - - 1.58 1.16-2.15 0.004
pT category 1.40 0.80-2.46 0.240 1.36 0.92-2.01 0.127
pN category 2.95 1.89-4.62 <0.001 2.93 2.07-4.15 <0.001
aCox’s proportional hazards regression analysis (Forward stepwise)
HR, hazard ratio
95 % CI, 95 % confidence interval
-,unavailable
Fig. 6 Two cohorts both showed that TRPV6 played a contradicting role in predicting survival of male and female patients. Downregulation of
TRPV6 was associated with a poor 3-year disease specific survival in patients with male in mRNA (a) and protein cohort (c). Downregulation of
TRPV6 was significantly associated with favorable 3-year disease specific survival in patients with female in mRNA (b) and protein cohort (d)
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strong rationale to explore its expression pattern in dif-
ferent cancer types. By far, this is the first comprehensive
study to report that TRPV6 is down-regulated in ESCC.
Furthermore, our present study showed that patients
with downregulation of TRPV6 trend to have a higher
rate of advanced pT stage in both mRNA cohort and
protein cohort, but the result is not statistically signifi-
cant. Our findings suggested that TRPV6 might have
tumor-suppressive ability and inhibit the progression of
ESCC. Previous studies have indicated that TRPV6
might play a protective role in some cancers [17, 18].
For instance, one study showed that TRPV6 can mediate
capsaicin-induced apoptosis in gastric cells [18]. TRPV6
seems to display differing roles in the progression and
proliferation of cancer dependent on cellular context.
Thereby, further studies in vitro and in vivo are ongoing
to clarify its tumor-suppressive ability and the precise
mechanisms in ESCC.
The potential of TRPV6 as a marker to predict the
clinical outcome of cancers has been well-established
[9, 14, 27]. Substantial expression of TRPV6 mRNA
increases with the degree of aggressiveness of the
cancer and the degree of metastasis outside the pros-
tate in patients with prostate cancer [9, 27]. Addition-
ally, breast cancer patients with high expression of
TRPV6 have a worse survival when compared to those
with low or intermediate TRPV6 expression [14]. Al-
though patients with downregulation of TRPV6 trend to
have a poorer 3-year DSS, no significant association is ob-
served between TRPV6 expression and survival of ESCC
patients. Interestingly, stratified survival analysis based on
the gender in two cohorts showed that downregulation of
TRPV6 is significantly associated with an unfavorable 3-
year DSS in male patients, while downregulation of
TRPV6 is significantly related with favorable 3-year DSS
in female patients. This result is the first time to suggest
that TRPV6 plays a Janus-like role in predicting survival
of male and female patients with ESCC. Epidemiological
studies have revealed that male patients has a worse prog-
nosis than female patients with esophageal cancer [27, 28].
More attentions should be paid to focusing on prognostic
predictor for tailoring more effective therapies in male
patients with ESCC. Our result found that male patients
with downregulation of TRPV6 have a worse survival than
those with normal level of TRPV6. This finding exhibits
important clinical significance in determining TRPV6 ex-
pression status and identifying patients subpopulation at
high risk of cancer-specific mortality, indicating that male
patients with downregulation of TRPV6 are likely to bene-
fit from adjuvant treatment.
Previous studies indicated that the expression of
TRPV6 is directly or indirectly regulated by sex steroid
hormones [8, 29–31]. TRPV6 was found to be negatively
regulated by androgen in prostate cancer cell line [29].
In the presence of the specific androgen receptor antag-
onist, Casodex, TRPV6 mRNA level increases 2-fold
over 2 days in a time-dependent manner. Meanwhile,
addition of dihydrotestosterone (DHT) reduces TRPV6
mRNA level 80 % within one day. On the other hand, the
expression of TRPV6 is up-regulated in time-dependent
manner by estradiol and progesterone in breast cancer cell
line [8]. These observations shed lights on why TRPV6
plays a mixed role in predicting survival of male and
female patients with ESCC. However, further studies are
needed to clarify the precise mechanisms.
We acknowledged that our study suffered from several
limitations. To better elucidate the role of TRPV6 in
cancers, the following challenges should be met in the
future. First of all, our cohort study was retrospective
study, which may lead to selection bias. Prospective
studies are required to confirm its prognostic signifi-
cance. Second, although this is the first study reporting
TRPV6 is down-regulated in ESCC, the role of TRPV6
in proliferation and invasion of ESCC in vitro and vivo
are yet to be elucidated. Further researches for cell cycle
analysis, apoptosis analysis, invasion assays and tumor
formation in vivo are required to explore the tumor-
suppressive ability of TRPV6 and its related pathway.
Third, the mechanism by which TRPV6 imposes oppos-
ite on survival of male and female patients with ESCC
was not investigated in our study. Further researches
about the plausible interaction between TRPV6 and sex
hormones in ESCC are needed to unveil the precise
mechanism.
Conclusions
In summary, for the first time, we clarified that the ex-
pression of TRPV6 in mRNA and protein level was
down-regulated in ESCC tissues. Analysis of two inde-
pendent cohorts suggested that as a predictive bio-
marker, TRPV6 plays a Janus-like role in predicting
survival of male and female patients.
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